{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:58:54Z","timestamp":1780948734458,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Studies launched in Japan on once-weekly teriparatide (1\/W-TPTD) and twice-weekly teriparatide (2\/W-TPTD) are limited. Therefore, we examined the effects of sequential therapy using anti-resorptive agents after administering 1\/W-TPTD and 2\/W-TPTD using dual-energy X-ray absorptiometry (DXA) and DXA-based 3D modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a multicenter retrospective study following a phase 3 clinical trial called the TWICE study. Two-year follow-up data were collected after administering 1\/W-TPTD or 2\/W-TPTD for 1 year (follow-up after the phase 3 clinical trial).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>20 subjects in the group of pre-treatments with 1\/W-TPTD followed by sequential administration of bisphosphonate or denosumab (1\/W-TPTD [BP\/denosumab]), and 22 in the group 2\/W-TPTD (BP\/denosumab) were included in the analysis of changes in the BMD by post-treatment. In the 1\/W-TPTD (BP\/denosumab) group, a significant increase in L2\u20134 BMD was observed. In the 2\/W-TPTD (BP\/denosumab) group, a significant increase in total hip, neck, and L2\u20134 BMD values was observed. Analysis by 3D-SHAPER revealed that both the 1\/W-TPTD (BP\/denosumab) and 2\/W-TPTD (BP\/denosumab) groups demonstrated significant increases in cortical sBMD and vBMD 2 years after the initiation of post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In subjects who received 1\/W-TPTD and 2\/W-TPTD for about 1 year followed by sequential administration of BP or denosumab, significant improvements in BMD were continuously observed. Furthermore, significant improvements in cortical sBMD and vBMD were also demonstrated by analysis using 3D-SHAPER. Both 1\/W-TPTD and 2\/W-TPTD were effective in the treatment of osteoporosis by using anti-resorptive agents for sequential administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-026-01690-7","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T10:12:00Z","timestamp":1769854320000},"page":"363-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide"],"prefix":"10.1007","volume":"44","author":[{"given":"Hidehiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4577-5072","authenticated-orcid":false,"given":"Manabu","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobukazu","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsugu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ikejiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Oha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Shigenobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1690_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00198-017-4009-0","volume":"28","author":"JA Kanis","year":"2017","unstructured":"Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023\u20132034","journal-title":"Osteoporos Int"},{"key":"1690_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) Scientific advisory board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"1690_CR3","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1210\/jc.2014-1041","volume":"99","author":"KK Nishiyama","year":"2014","unstructured":"Nishiyama KK, Cohen A, Young P, Wang J, Lappe JM, Guo XE, Dempster DW, Recker RR, Shane E (2014) Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. J Clin Endocrinol Metab 99:2418\u20132425","journal-title":"J Clin Endocrinol Metab"},{"key":"1690_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/01926230252929882","volume":"30","author":"JL Vahle","year":"2002","unstructured":"Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1\u201334) for 2 years and relevance to human safety. Toxicol Pathol 30:312\u2013321","journal-title":"Toxicol Pathol"},{"key":"1690_CR5","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1080\/01926230601072301","volume":"34","author":"J Jolette","year":"2006","unstructured":"Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34:929\u2013940","journal-title":"Toxicol Pathol"},{"key":"1690_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1359\/JBMR.050501","volume":"20","author":"R Prince","year":"2005","unstructured":"Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507\u20131513","journal-title":"J Bone Miner Res"},{"key":"1690_CR7","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1210\/jc.2008-2630","volume":"94","author":"BZ Leder","year":"2009","unstructured":"Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS (2009) Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab 94:2915\u20132921","journal-title":"J Clin Endocrinol Metab"},{"key":"1690_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"1690_CR9","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gl\u00fcer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736","journal-title":"J Bone Miner Res"},{"key":"1690_CR10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1185\/03007995.2012.761956","volume":"29","author":"T Sugimoto","year":"2013","unstructured":"Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195\u2013203","journal-title":"Curr Med Res Opin"},{"key":"1690_CR11","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.eprac.2021.05.012","volume":"27","author":"T Kocjan","year":"2021","unstructured":"Kocjan T, Rajic AS, Janez A, Vidmar G, Orehek N, Marc J, Ostanek B (2021) Switching to denosumab or bisphosphonates after completion of teriparatide treatment in women with severe postmenopausal osteoporosis. Endocr Pract 27:941\u2013947","journal-title":"Endocr Pract"},{"key":"1690_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, Martin JS, Mu\u00f1oz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87\u201394","journal-title":"Osteoporos Int"},{"key":"1690_CR13","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki Ml (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1-34] once-weekly efficacy research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"key":"1690_CR14","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s00198-019-05111-6","volume":"30","author":"T Sugimoto","year":"2019","unstructured":"Sugimoto T, Shiraki M, Fukunaga M, Kishimoto H, Hagino H, Sone T, Nakano T, Ito M, Yoshikawa H, Minamida T, Tsuruya Y, Nakamura T (2019) Study of twice-weekly injections of teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. Osteoporos Int 30:2321\u20132331","journal-title":"Osteoporos Int"},{"key":"1690_CR15","first-page":"9","volume":"21","author":"The Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for Revision of Diagnostic Criteria for Primary Osteoporosis","year":"2013","unstructured":"The Japanese Society for Bone and Mineral Research and Japan Osteoporosis Society Joint Review Committee for Revision of Diagnostic Criteria for Primary Osteoporosis (2013) Diagnostic criteria for primary osteoporosis (2012 revised version). Osteoporosis Japan 21:9\u201321","journal-title":"Osteoporosis Japan"},{"key":"1690_CR16","doi-asserted-by":"publisher","first-page":"1111020","DOI":"10.3389\/fbioe.2023.1111020","volume":"1","author":"A Dudle","year":"2023","unstructured":"Dudle A, Gugler Y, Pretterklieber M, Ferrari S, Lippuner K, Zysset P (2023) 2D\u20133D reconstruction of the proximal femur from DXA scans: Evaluation of the 3D-Shaper software. Front Bioeng Biotechnol 1:1111020","journal-title":"Front Bioeng Biotechnol"},{"key":"1690_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00198-022-06570-0","volume":"34","author":"S Mori","year":"2023","unstructured":"Mori S, Hagino H, Sugimoto T, Tanaka S, Mitomo Y, Takahashi K, Sone T, Nakamura T, Soen S (2023) Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 34:189\u2013199","journal-title":"Osteoporos Int"},{"key":"1690_CR18","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"19","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA (2015) denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 19:1147\u20131155","journal-title":"Lancet"},{"key":"1690_CR19","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00198-022-06495-8","volume":"33","author":"JW Shin","year":"2022","unstructured":"Shin JW, He Q, Suk YJ, Kim SH, Kim HS (2022) Comparison of the efficacy between sequential therapy with teriparatide and denosumab and denosumab monotherapy in suppressing fragility fracture risk. Osteoporos Int 33:2409\u20132416","journal-title":"Osteoporos Int"},{"key":"1690_CR20","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00198-018-4624-4","volume":"29","author":"R Winzenrieth","year":"2018","unstructured":"Winzenrieth R, Humbert L, Di Gregorio S, Bonel E, Garc\u00eda M, Del Rio L (2018) Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling. Osteoporos Int 29:2323\u20132333","journal-title":"Osteoporos Int"},{"key":"1690_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jbmr.4739","volume":"38","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Shiau S, Kamanda-Kosseh M, Bucovsky M, Kil N, Lappe JM, Stubby J, Recker RR, Guo XE, Shane E, Cohen A (2023) Teriparatide followed by denosumab in premenopausal idiopathic osteoporosis: bone microstructure and strength by HR-pQCT. J Bone Miner Res 38:35\u201347","journal-title":"J Bone Miner Res"},{"key":"1690_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116416","volume":"160","author":"K Chiba","year":"2022","unstructured":"Chiba K, Okazaki N, Kurogi A, Watanabe T, Mori A et al (2022) Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: the TERABIT study. Bone 160:116416","journal-title":"Bone"},{"key":"1690_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.03.042","volume":"99","author":"R Zebaze","year":"2017","unstructured":"Zebaze R, Takao-Kawabata R, Peng Y, Zadeh AG, Hirano K, Yamane H, Takakura A, Isogai Y, Ishizuya T, Seeman E (2017) Increased cortical porosity is associated with daily, not weekly, administration of equivalent doses of teriparatide. Bone 99:80\u201384","journal-title":"Bone"},{"key":"1690_CR24","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/mrcr\/rxab048","volume":"6","author":"M Tsukamoto","year":"2022","unstructured":"Tsukamoto M, Okimoto N, Mori M, Yoshioka T, Asano K, Ikejiri Y, Uzawa T, Yoshimura T, Suzuki H, Yamanaka Y, Kawasaki M, Sakai A (2022) Bone microstructure changes due to once-\/twice-weekly teriparatide administration: a report of five cases using high-resolution peripheral quantitative computed tomography. Mod Rheumatol Case Rep 6:301\u2013304","journal-title":"Mod Rheumatol Case Rep"},{"key":"1690_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01415-1","volume":"19","author":"J Takada","year":"2024","unstructured":"Takada J, Okimoto N, Tsukamoto M, Akatsuka T, Takebayashi T, Iba K, Ikeda S (2024) Effects of differences in dose and frequency of teriparatide on bone structure in proximal femur. - analysis by DXA-based 3D-modeling (3D-SHAPER software) -TRIPLE-BONE study (the effects of TeRIParatide preparation on bone mineraL density increase and BONE structure). Arch Osteoporos 19:55","journal-title":"Arch Osteoporos"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01690-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01690-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01690-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:10:31Z","timestamp":1780945831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-026-01690-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01690-7","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Tsukamoto has received payments for lectures from Asahi Kasei Pharmaceutical Co., Ltd and fees for medical advice from Zimmer Biomet G.K. N. Okimoto has received payments for lectures, including speakers\u2019 bureau fees from Asahi Kasei Pharmaceutical Co., Ltd.; Amgen K.K.; Astellas Pharma Inc.; Daiichi-Sankyo Co., and Teijin Pharma Ltd. S. Ikeda has received consulting fees, speaking fees, and\/or honoraria from Amgen Inc., Asahi Kasei Pharma Corp., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Pfizer Inc., Hisamitsu Pharmaceutical Co., Inc., Mochida Pharma Co., Ltd., Teijin Pharma Ltd., Towa Pharmaceutical Co., Ltd., and UCB Japan Co., Ltd. K. Shigenobu has received payments for lectures from Asahi Kasei Pharmaceutical Co., Ltd. A. Sakai has received payments for lectures from Asahi Kasei Pharmaceutical Co., Ltd and Teijin Pharma Ltd. J. Takada received payments for lectures and medical advice from Asahi Kasei Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}